NASDAQ:CERO CERo Therapeutics Q3 2025 Earnings Report $0.01 +0.00 (+17.89%) As of 03:36 PM Eastern ProfileEarnings HistoryForecast CERo Therapeutics EPS ResultsActual EPS-$9.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACERo Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACERo Therapeutics Announcement DetailsQuarterQ3 2025Date11/19/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsCERo Therapeutics' next earnings date is estimated for Wednesday, September 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile CERo Therapeutics Earnings HeadlinesCERo Therapeutics Expands Convertible Debt Financing ArrangementJuly 17, 2026 | tipranks.comNasdaq, Inc.: Delisting of Securities from The Nasdaq Stock MarketJuly 11, 2026 | finanznachrichten.de$100 for this… $500 for that. Here’s how to stop the bleeding todayRising costs are squeezing households nationwide. USA Today reports more families are moving in together, while Yahoo notes retirees are searching for roommates just to make ends meet. Larry Benedict, who ran one of Wall Street's most successful trading funds for 40 years, shares the approach he used with major clients to navigate volatile markets.August 14 at 1:00 AM | Brownstone Research (Ad)CERo Therapeutics Holdings, Inc. Common Stock (CERO)June 25, 2026 | nasdaq.comCERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following TreatmentJune 15, 2026 | globenewswire.comCERo Therapeutics Raises Funding via Convertible Note FinancingMay 29, 2026 | tipranks.comSee More CERo Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CERo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CERo Therapeutics and other key companies, straight to your email. Email Address About CERo TherapeuticsCERo Therapeutics (NASDAQ:CERO), an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.View CERo Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More DividedCAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationQuantum Leaps: Debt-Free as AI Storage Demand AcceleratesFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care? Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
